Orasure Technologies Inc(OSUR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.69 | Insider Own | 6.61% | Shs Outstand | 69.0M | Perf Week | 12.61% |
| Market Cap | 0.27B | Forward P/E | - | EPS next Y | -22.73% | Insider Trans | 1.67% | Shs Float | 64.4M | Perf Month | 3.97% |
| Enterprise Value | 0.13B | PEG | - | EPS next Q | -0.23 | Inst Own | 88.64% | Short Float | 4.93% | Perf Quarter | -10.88% |
| Income | -0.05B | P/S | 2.41 | EPS this Y | 29.79% | Inst Trans | -3.47% | Short Ratio | 6.57 | Perf Half Y | 25.16% |
| Sales | 0.11B | P/B | 0.85 | EPS next 5Y | - | ROA | -12.2% | Short Interest | 3.17M | Perf YTD | 62.4% |
| Book/sh | 4.61 | P/C | 1.69 | EPS past 3/5Y | -58.18% -33.45% | ROE | -14.07% | 52W High | -14.19% ($4.58) | Perf Year | 21.67% |
| Cash/sh | 2.33 | P/FCF | - | Sales past 3/5Y | -33.29% -7.7% | ROIC | -14.75% | 52W Low | 88.94% ($2.08) | Perf 3Y | -30.44% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -0.63% | Gross Margin | 38.89% | Volatility(W/M) | 5.32% 3.94% | Perf 5Y | -63.98% |
| Dividend TTM | - | EV/Sales | 1.14 | Sales Y/Y TTM | -18.86% | Oper. Margin | -64.85% | ATR (14) | 0.16 | Perf 10Y | -52.71% |
| Dividend Ex-Date | - | Quick Ratio | 7.68 | EPS Q/Q | 133.72% | Profit Margin | -43.7% | RSI (14) | 62.16 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.88 | Sales Q/Q | -1.93% | SMA20 | 10.28% ($3.56) | Beta | 1.03 | Target Price | $4 |
| Payout | - | Debt/Eq | 0.05 | Earnings | 2026/8/5 | SMA50 | 4.12% ($3.77) | Rel Volume | 1.43 | Prev Close | $3.99 |
| Employees | 501 | LT Debt/Eq | 0.05 | EPS/Sales Surpr. | 133.33% 5.29% | SMA200 | 17.95% ($3.33) | Avg Volume(3M) | 0.48M | Price | $3.93 |
| IPO | 1986/11/17 | Option/Short | Yes/Yes | Trades | 3397 | Volume | 693,262 | Change | -1.5% |
Company
OSUR is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧪 OraSure Technologies is a U.S. medical device company that supplies rapid diagnostic tests based on oral fluid and sample collection/preservation solutions. It operates with two main pillars: the OraQuick line of tests, which quickly screen for HIV and Hepatitis C at the point of care, and sample collection devices for molecular diagnostics. These products are widely used by public health agencies, telehealth providers, and direct-to-consumer channels.
Over the past 1 year, roughly in the middle
14% below its 1-year high.
OSUR has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +29.8% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Would have changed by -30.4% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 88.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
HULL 0.01%
QQQS 0.01%
SVAL 0.00%
RUSC 0.00%
IWC 0.00%It ranks #4 in the industry
Based on market cap of $271M.
OSUR $271M PER -
ISRG $141B PER 45.8
BDX $49B PER 54.1
MDLN $46B PER 40.6
FAQ
What kind of company is OSUR?
OSUR belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of OSUR?
The market cap of OSUR is approximately $271M, ranking 3,824 within its sector.
What is the 52-week high and low for OSUR?
OSUR has recorded a 52-week high of $4.58 and a low of $2.08.
